Connect with us

Headlines

New Blindness Treatment to Cost $850,000

mm

Published

on

It’s one of the most expensive drugs ever produced.

A newly approved treatment for a genetic form of blindness will cost $850,000, Bloomberg reports.

Luxturna, developed by Spark Therapeutics, recently received the OK from the U.S. Food and Drug Administration. It treats a rare inherited disorder called retinal dystrophy, which affects 1,000 to 2,000 people in the U.S.

Luxturna is a one-time treatment that involves injecting a replacement gene into the retina, the Associated Press reports. It costs $425,000 per eye.

AP describes the breakthrough treatment as “one of the most expensive medicines in the world” and notes that it is prompting questions about “the affordability of a coming wave of similar gene-targeting therapies.”

Advertisement

Bloomberg notes that Spark Therapeutics is working out unique arrangements with insurers, such as “discounts based on whether or not the drug works initially and remains effective.” It may also allow payments for the medication to be made over time.

Read more at Bloomberg

SPONSORED VIDEO

Meet the Next Generation of Smart Glasses

Ray-Ban Meta is now available with a full range of lenses, as a complete pair or edged lens. Prescription orders eligible through select insurance providers, including Eyemed and private pay. The Ray-Ban Meta collection combines iconic design with cutting-edge technology. Capture life’s best moments and livestream to Facebook and Instagram with an upgraded 12 MP camera and five-mic system. Stay connected with hands-free calls and messages. Listen to your favorite tracks through built-in speakers. Spark your creativity, get information and control your glasses with your voice – powered by Meta AI. All while keeping your phone in your pocket. For more information, visit here.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular